HHC, THCP and Semi-Synthetic Cannabinoids: A Retailer's Briefing

Where These Compounds Came From

Hexahydrocannabinol (HHC) was the first semi-synthetic cannabinoid reported in the European Union, and has been monitored by the EU Early Warning System since October 2022. It is not extracted from the plant in the way CBD is — it is produced by chemically modifying CBD extracted from low-THC hemp.

That production route is the whole reason the category exists. Starting from lawful hemp-derived CBD and converting it into a different, intoxicating compound placed these products in a regulatory space that had not been written with them in mind. Related compounds including HHC-P and THCP followed the same commercial path.

The European Union Drugs Agency covers the emergence of the category in its briefing on HHC and the evolving cannabinoid market, and maintains a broader topic page on synthetic cannabinoids.

Why This Is Not the Same Risk as CBD

Three differences matter for anyone deciding what to put on a shelf.

• These compounds are intoxicating. Unlike CBD, HHC and its relatives produce psychoactive effects. Whatever the legal position in a given market, that changes the customer conversation and the duty of care entirely.
• The regulatory position has been moving quickly. Semi-synthetic cannabinoids have been the subject of national bans, controlled-substance scheduling, and international control measures — with different countries acting at different times. A product lawful when ordered may not be lawful when it arrives.
• The evidence base is thin. These are recent compounds with far less published research behind them than CBD. That is a genuine unknown, not a marketing objection.

The Practical Problem for Retailers

The commercial appeal is obvious — intoxicating products carry higher margins and attract customers CBD alone does not. The difficulty is that the risk is not evenly distributed across your business. Stocking a controlled substance, even unknowingly, is a different order of problem from a labelling dispute, and it can affect banking, insurance and licences well beyond the individual product line.

Because national positions differ and have changed repeatedly, the only reliable approach is to verify the current status in your own market at the time of ordering, from a national authority rather than from a supplier's marketing page.

What We Stock, and Why

Our catalogue is built on hemp-derived, lab-tested products within legal THC limits — flowers, hash and resin, oils and edibles — rather than semi-synthetic cannabinoids. That is a deliberate positioning decision. It keeps our customers' compliance picture straightforward and means a certificate of analysis is sufficient documentation for what they are selling.

For retailers who want stronger-selling products without stepping into that risk category, the practical routes are aroma and quality rather than intoxication: premium indoor flower, high-percentage filtered resins, or novelty formats such as MoonRock and Ice Rock that command a premium on presentation.

If You Do Decide to Stock Them

Verify the legal status in writing, from a national source, dated. Keep documentation for every batch. Age-gate rigorously. And understand that the regulatory position may change between ordering and selling — several markets have moved from permissive to prohibited within a single season.

For the wider legal picture on cannabinoids in Europe, see our country overview and the blog guide to CBD legality across Europe. As with all regulatory content here, this is general information for retailers rather than legal advice.